Cost-effectiveness of pharmacogenomic-guided treatment for major depression.

ABSTRACT:

Background

Pharmacogenomic testing to identify variations in genes that influence metabolism of antidepressant medications can enhance efficacy and reduce adverse effects of pharmacotherapy for major depressive disorder. We sought to establish the cost-effectiveness of implementing pharmacogenomic testing to guide prescription of antidepressants.

Methods

We developed a discrete-time microsimulation model of care pathways for major depressive disorder in British Columbia, Canada, to evaluate the effectiveness and cost-effectiveness of pharmacogenomic testing from the public payer's perspective over 20 years. The model included unique patient characteristics (e.g., metabolizer phenotypes) and used estimates derived from systematic reviews, analyses of administrative data (2015

SUBMITTER: Ghanbarian S 

PROVIDER: S-EPMC10699479 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature